Antibody fragments are an emerging area of focus within the monoclonal antibody community and they represent a new class of therapeutics. Due to their smaller molecular size, antibody fragments have a number of therapeutic advantages over whole antibodies.
(Antibody Fragment Model)
The primary advantage of human antibody fragments is their
Improved tissue penetration versus whole antibodies.
Potential for local and topical delivery versus parenteral administration of whole antibodies.
Low systemic drug levels resulting in fewer unwanted drug side effects.
Ability to be manufactured in microbial expression systems.
